Ergomed (ERGO) Given Corporate Rating at N+1 Singer

N+1 Singer reiterated their corporate rating on shares of Ergomed (LON:ERGO) in a research report released on Friday.

Separately, Numis Securities restated a buy rating and issued a GBX 275 ($3.70) price objective on shares of Ergomed in a report on Tuesday, September 19th.

Ergomed (LON:ERGO) traded up GBX 2.50 ($0.03) during mid-day trading on Friday, hitting GBX 187.50 ($2.52). The company had a trading volume of 28,310 shares, compared to its average volume of 23,449. Ergomed has a 12-month low of GBX 145 ($1.95) and a 12-month high of GBX 225 ($3.03).

Ergomed (LON:ERGO) last released its quarterly earnings data on Monday, September 18th. The company reported GBX 1.20 ($0.02) earnings per share for the quarter. The firm had revenue of GBX 2,291 million during the quarter. Ergomed had a return on equity of 2.69% and a net margin of 2.07%.

COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at

Ergomed Company Profile

Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services.

What are top analysts saying about Ergomed? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ergomed and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit